Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.

ABSTRACT:

Aims

Impaired myocardial energy homeostasis plays an import role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). Left ventricular relaxation has a high energy demand, and left ventricular diastolic dysfunction has been related to impaired energy homeostasis. This study investigated whether trimetazidine, a fatty acid oxidation inhibitor, could improve myocardial energy homeostasis and consequently improve exercise haemodynamics in patients with HFpEF.

Methods and results

The DoPING-HFpEF trial was a phase II single-centre, double-blind, placebo-controlled, randomized cross-over trial. Patients were randomized to trimetazidine treatment or placebo for 3 months and switched after a 2-week wash-out period. The primary endpoint was change in pul

SUBMITTER: van de Bovenkamp AA 

PROVIDER: S-EPMC10567667 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature